



Submitted by: Chief Medical Officer
Name: Johnathan Lancaster, MD, PhD
Company/Organization: Myriad Genetic Laboratories, Inc.
Address: 320 Wakara Way, Salt Lake City, UT 84108
Phone: 801-505-5090
Email: jlancaster@myriad.com
Date of request: May 14, 2016
NCCN Guidelines Panel: Genetic/Familial High Risk Assessment: Breast and Ovarian

Specific Changes:

On BRCA-1 at the top, replace “*BRCA1/2* testing criteria” with “Hereditary Breast and Ovarian cancer genes (which besides *BRCA1/2* may include Lynch syndrome genes, *CDH1*, *STK11*, *BRIP1*, *PALB2*, *RAD51C*, *RAD51D*, *CHEK2* and *ATM*).”

- 1) Add the following footnote to the new testing criteria
 - a. Due to the link between breast cancer and multiple genes implicated in hereditary cancer syndromes, testing for a multigene panel should be strongly considered as an alternative to *BRCA1/2* testing alone.

FDA Clearance: Not applicable.

Rationale: We ask NCCN to support the option of testing for other genes when testing for *BRCA1/2*. Multiple gene have been implicated as hereditary breast and ovarian cancer genes. In addition to *BRCA1* and *BRCA2*, genes with specific NCCN guidelines include, the Lynch syndrome genes, *CDH1*, *STK11*, *ATM*, *BRIP1*, *CHEK2*, *PALB2*, *RAD51C*, and *RAD51D*. See pages ADDIT-1 and ADDIT-2 of these guidelines in addition to other NCCN guidelines.

This change is requested to maintain consistency for providers among the multiple guidelines.

Sincerely,

Johnathan Lancaster, MD, PhD
Chief Medical Officer, Myriad Genetic Laboratories Inc.